Global diabetic macular edema market is expected to have a princely growth due to the increasing cases of diabetes all around the world. With investments in research and development by major companies, the market is projected to witness a substantial rise during the forecast period. Some of the recent developments by the major companies are mentioned below.
Roche in February 2021 announced their phase III results of the bispecific antibody farcimab for the treatment of diabetic macular edema. Patients for trial were able to be treated every four months in DME and nAMD. Farcimab is the first eye injectable medicine to achieve this length of time between treatments. Farcimab was generally well tolerated in the four studies without any new unexpected safety signals. Farcimab offers treatment to two most prevalent causes of blindness, i.e. diabetic macular edema and neovascular age related macular degeneration.
Novartis in September 2020 reported positive results from the first phase III trial of Beovu versus aflibercept in patients with diabetic macular edema. In phase III, Beovu 6mg achieved its primary endpoint of non-inferiority to aflibercept 2mg in mean change in best corrected visual acuity. The trial met all the primary and secondary endpoints and demonstrated non inferiority for Beovu versus aflibercept 2mg in mean change in best corrected visual acuity. The trial was conducted where patients were on a two month dosing interval after the loading phase. The result demonstrated that the rate of ontraocular inflammation was equivalent between Beovu and Aflibercept.
Bayer in India in September 2020 announced the approval of their Aflibercept injection for intravitreal, a solution to treat diabetic macular edema. Intravitreal Alfibercept offers help among patients impacted by diabetic vision loss to maintain their vision and to continue participating in daily activities. The therapies like this reduce swelling and helps in restoring central vision. The company aims to provide access to treatment through their patient support program and also by financing partnership for patients.
Future Market Insights forecasts the global diabetic macular edema market to grow from nearly US$ 3,710 Mn in 2017 to over US$ 4,100 Mn by 2027 end. This represents a CAGR of 1.1% over the forecast period of 2017– 2027. North America is projected to be the largest market in terms of value and accounted for the highest revenue share of 51.5% in 2016.
Growing adoption of recently approved Intravitreal implants in North America
Before the launch of Lucentis for DME treatment in 2012, the use of intravitreally injected medications was less common in North America and laser photocoagulation was the primary treatment. However, Avastin and Macugen were being used off-label for diabetic macular edema treatment since 2004. Launch of three new products in 2014 viz.
Eylea, Ozurdex and Iluvien, has led to the increased adoption of Intravitreal medications in North America. For instance, according to estimates of the University of Washington, before 2004, 5.75% of DME patients used Intravitreal injections, which increased to 20% by 2013. In 2016, over 70% of DME patients were utilising Intravitreal injections and implants.
This sudden increase in the adoption of Intravitreal therapies can be attributed to the launch of low dose high efficacy corticosteroid implants for Intravitreal use. Uptake of Intravitreal implants by new patients as well as by patients previously treated with Intravitreal injections but who do not show any improvement, is expected to push the market for diabetic macular edema in the region.
Growing economic burden of diabetes and related disorders
Diabetic Macular Edema (DME) is a leading cause of blindness among the working age population in most developed countries. DME is one of the major complications of diabetes and DME patients utilise significantly higher healthcare resources than non-DME diabetic patients. As per a survey conducted by the University of Washington, the total yearly median cost for DME patients was reported to be US$ 14,678 and that for non-DME diabetic patients was US$ 6,801 in 2011.
Moreover, DME patients have to visit their physicians for at least 30 days per year in contrast to an average of 14 visits per year in the case of non-DME diabetic patients. The growing incidences of diabetes across the globe further increase the burden of DME. According to the International Diabetic Federation (IDF), 382 Mn people worldwide have diabetes and the number is expected to grow to 592 Mn by 2035.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Gaps in making DME a health priority hampering market growth in North America
Although control of diabetes is made a health priority in developed countries such as the U.S., much attention is not given to DME management and diabetes related caregivers tend to focus on the treatment of other diabetic complications. The major reason for this is the lack of effective treatment for DME. Even though anti-VEGF and corticosteroid therapies have changed the treatment paradigm, there exists a gap in patients’ clinical information among clinicians.
Furthermore, there exists an error in industry sponsored and independently run clinical trials. For instance, there are approximately 72 independent clinical trials going on for DME treatment, but most of them lack long-term results regarding safety and efficacy on new and combination therapies for diabetic macular edema. These factors are hampering revenue growth of the diabetic macular edema market in North America.
Global Diabetic Macular Edema Market Attractiveness Analysis, By Region
Western Europe is expected to be the most lucrative market for diabetic macular edema, with market attractiveness index of 2.7. Major players in the diabetic macular edema market, including Bayer AG and Novartis AG, are focussing on improving the sale of Eylea and Lucentis, respectively, in Europe.
Companies are trying to exploit the full market potential and get maximum returns on R&D till patents for their drugs are alive. North America dominated the diabetic macular edema market in revenue terms in 2016, and the trend is projected to continue throughout the forecast period.
North America is expected to be the second most lucrative among all regions, with an attractiveness index of 2.5. APEJ represents the third largest market with a market attractiveness index of 0.4. MEA is expected to remain the least attractive regional market for diabetic macular edema in revenue terms, with an attractiveness index of 0.1 over the forecast period.
By Therapy Type
- Ranibizumab (Lucentis)
- Afilbercept (Eylea)
- Fluocinolone Acetonide (Iluvien)
- Dexamethasone (Ozurdex)
- Other Off-label Drugs (Triamcinolone Acetonide, Bevacizumab and Pegaptanib)
By Product Form
- Intravitreal Injections
- Intravitreal Implants
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- North America
- Latin America
- Western Europe
- Eastern Europe